These limitations are not specific to the CXCL10-based gene cluster model alone but to the development of any diagnostic biomarker, emphasizing the need for further research, validation, and collaboration among researchers to enhance diagnostic accuracy and clinical utility for POF. This evidence concerns the gene CXCL10 and premature menopause.